FGEN Company Profile and Key Details
FibroGen, Inc.
FGEN Stock Price Chart
Stock Price Today
FibroGen, Inc. (FGEN) stock declined over -6.19%, trading at $0.50 on NASDAQ, down from the previous close of $0.53. The stock opened at $0.53, fluctuating between $0.46 and $0.55 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Company Information
| Employees | 486 |
| Beta | 0.73 |
| Sales or Revenue | $147.75M |
| 5Y Sales Change% | -0.401% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
FibroGen, Inc. (NASDAQ: FGEN) stock price is $0.50 in the last trading session. During the trading session, FGEN stock reached the peak price of $0.55 while $0.46 was the lowest point it dropped to. The percentage change in FGEN stock occurred in the recent session was -6.19% while the dollar amount for the price change in FGEN stock was -$0.03.
The NASDAQ listed FGEN is part of Biotechnology industry that operates in the broader Healthcare sector. FibroGen, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Christine L. Chung
Senior Vice President of China Operations
Mr. Enrique A. Conterno
Chief Executive Officer & Director
Dr. Elias Kouchakji
Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance
Dr. Barry A. Berkowitz Ph.D.
Founder
Dr. John J. Hunter Ph.D.
Chief Scientific Officer
Dr. Mark Eisner M.D., M.P.H.
Executive Vice President & Chief Medical Officer
Mr. Michael D. Lowenstein J.D., Ph.D.
Chief Legal Officer
Mr. Thane Wettig
Interim Chief Executive Officer, Executive Vice President & Chief Commercial Officer
Mr. Juan Graham
Senior Vice President & Chief Financial Officer
Ms. Tricia Stewart
Chief People Officer
FGEN's closing price is 194.5% higher than its 52-week low of $0.18 where as its distance from 52-week high of $2.93 is -81.91%.
Number of FGEN employees currently stands at 486.
Official Website of FGEN is: https://www.fibrogen.com
FGEN could be contacted at phone 415 978 1200 and can also be accessed through its website. FGEN operates from 409 Illinois Street, San Francisco, CA 94158, United States.
FGEN stock volume for the day was 2.08M shares. The average number of FGEN shares traded daily for last 3 months was 1.42M.
The market value of FGEN currently stands at $50.11M with its latest stock price at $0.50 and 100.77M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com